Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection.
SARS-CoV-2
agranulocytosis
clozapine
neutropenia
schizophrenia
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
02
2022
accepted:
20
04
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed to provide a study on the association between neutropenia and clozapine in patients with schizophrenia and COVID-19. To assess the neutrophil count in patients with schizophrenia treated with clozapine and infected with COVID-19. The study patients with schizophrenia, according to DSM-5, admitted to the Clinical Hospital of Psychiatry and Neurology Brasov, Romania, between April 2020 and October 2021. The inclusion criteria included positive RT-PCR (real-time PCR) test for COVID-19 and treatment with clozapine. We assessed three values of ANC (absolute neutrophil count): before COVID-19 infection (last ANC obtained at mandatory check), during infection and 1 month after resolution (first negative PCR test). Of the 105 cases, 95 did not have neutropenia. Fifty-nine patients were males (62.1%), mean age was 43.5 years (SD = 12.1) with an average of clozapine treatment of 52.4 months (SD = 11.9). At baseline, they had a small reduction in the ANC mean value (4.41 × 109/l; SD = 2.22) which did not constitute a statistically significant decline from the prior to COVID-19 mean value of 4.66 × 109/l (SD = 2.34; p = 0.45). Values were also normal in the first month after negative PCR testing (4.45 × 109/l; SD = 2.35; p = 0.91). A total of 10 patients (9.5%) had neutropenia. The age, dose of clozapine and duration of treatment were not statistically different compared to the group without neutropenia. Psychiatrists and other health professionals should keep in mind that neutrophil count may decrease during COVID-19 infection in patients taking clozapine and in some cases, neutropenia may even occur. We assumed that neutropenia could be caused by COVID-19 and clozapine interaction.
Sections du résumé
Background
UNASSIGNED
Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed to provide a study on the association between neutropenia and clozapine in patients with schizophrenia and COVID-19.
Aim
UNASSIGNED
To assess the neutrophil count in patients with schizophrenia treated with clozapine and infected with COVID-19.
Methods
UNASSIGNED
The study patients with schizophrenia, according to DSM-5, admitted to the Clinical Hospital of Psychiatry and Neurology Brasov, Romania, between April 2020 and October 2021. The inclusion criteria included positive RT-PCR (real-time PCR) test for COVID-19 and treatment with clozapine. We assessed three values of ANC (absolute neutrophil count): before COVID-19 infection (last ANC obtained at mandatory check), during infection and 1 month after resolution (first negative PCR test).
Results
UNASSIGNED
Of the 105 cases, 95 did not have neutropenia. Fifty-nine patients were males (62.1%), mean age was 43.5 years (SD = 12.1) with an average of clozapine treatment of 52.4 months (SD = 11.9). At baseline, they had a small reduction in the ANC mean value (4.41 × 109/l; SD = 2.22) which did not constitute a statistically significant decline from the prior to COVID-19 mean value of 4.66 × 109/l (SD = 2.34; p = 0.45). Values were also normal in the first month after negative PCR testing (4.45 × 109/l; SD = 2.35; p = 0.91). A total of 10 patients (9.5%) had neutropenia. The age, dose of clozapine and duration of treatment were not statistically different compared to the group without neutropenia.
Conclusion
UNASSIGNED
Psychiatrists and other health professionals should keep in mind that neutrophil count may decrease during COVID-19 infection in patients taking clozapine and in some cases, neutropenia may even occur. We assumed that neutropenia could be caused by COVID-19 and clozapine interaction.
Identifiants
pubmed: 35547265
doi: 10.2147/NDT.S361405
pii: 361405
pmc: PMC9081886
doi:
Types de publication
Journal Article
Langues
eng
Pagination
977-983Informations de copyright
© 2022 Moga et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
BMC Psychiatry. 2016 Mar 22;16:76
pubmed: 27000113
J Affect Disord. 2014 Sep;166:168-72
pubmed: 25012427
Schizophr Res. 2020 Jun;220:265-266
pubmed: 32349886
Blood Rev. 2019 Sep;37:100586
pubmed: 31255364
Ther Adv Psychopharmacol. 2020 May 27;10:2045125320928167
pubmed: 32542111
Psychiatr Q. 2021 Jun;92(2):721-733
pubmed: 32918660
Thorax. 2013 Nov;68(11):1057-65
pubmed: 24130229
Ther Adv Psychopharmacol. 2020 Sep 13;10:2045125320959560
pubmed: 32974002
J Clin Psychiatry. 2015 Nov;76(11):e1410-6
pubmed: 26646037
J Clin Psychiatry. 2016 Jul;77(7):e909-16
pubmed: 27464332
Psychosomatics. 2020 Sep - Oct;61(5):577-578
pubmed: 32593477
J Natl Cancer Inst. 2003 Oct 15;95(20):1545-8
pubmed: 14559877
J Psychiatry Neurosci. 2021 Mar 11;46(2):E232-E237
pubmed: 33703870
Br J Psychiatry. 2020 Sep;217(3):471-474
pubmed: 32362299
J Clin Psychiatry. 1998;59 Suppl 3:38-43
pubmed: 9541337
Schizophr Bull. 2020 Jul 8;46(4):752-757
pubmed: 32343342
J Psychiatry Neurosci. 2020 Apr 03;45(3):222-223
pubmed: 32297722
Clin Pharmacokinet. 2003;42(7):607-18
pubmed: 12844323
Ann Intern Med. 2007 Apr 3;146(7):486-92
pubmed: 17404350
Acta Psychiatr Scand. 2018 Aug;138(2):101-109
pubmed: 29786829
Ther Adv Psychopharmacol. 2020 Jul 16;10:2045125320940935
pubmed: 32728419
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):38-42
pubmed: 27913460
Neuropsychiatr Dis Treat. 2021 Oct 02;17:3053-3060
pubmed: 34629871
Brain Behav Immun Health. 2021 May;13:100212
pubmed: 33527097
Br J Psychiatry. 2021 Jul;219(1):368-374
pubmed: 32713374
Schizophr Bull. 2020 Jul 8;46(4):751
pubmed: 32435811
Arch Gen Psychiatry. 1988 Sep;45(9):789-96
pubmed: 3046553